ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Compass Therapeutics (CMPX)
Compass Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.75▼ -1.81%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Compass Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Compass Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Compass Therapeutics a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.62 and $0.86; in 9 out of 10, between $0.46 and $1.15. Estimated annual volatility is 101%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $154M
- 52-week high
- $6.88
- 52-week low
- $0.74
- Revenue (12 months)
- $0.0M
- Revenue growth (YoY)
- -100.0%
- Return on equity
- -56.7%
- Free cash flow (12 months)
- $-31.4M
- Beta
- 0.85
What this means
ATLAS does not publish a fair value for CMPX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CMPX has traded between $0.74 and $6.88. Today it is 89.1% below that high and 1% above its low.
Its beta is 0.85: it moves roughly in line with the market.
About the company
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer.
Want to see everything about Compass Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Compass Therapeutics do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer.
What is the chance CMPX goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, CMPX ends the month between $0.62 and $0.86.
How big is Compass Therapeutics and what is its P/E ratio?
Compass Therapeutics's market capitalization is $154M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is CMPX?
ATLAS estimates annual volatility at 101%. In a typical month, half of the outcomes end between $0.62 and $0.86.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer